What are the recommended liver cancer screening guidelines for an adult with metabolic‑dysfunction‑associated steatohepatitis?

Liver Cancer Screening in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Hepatocellular carcinoma surveillance should be applied to all patients with MASH-related cirrhosis using semi-annual ultrasound combined with alpha-fetoprotein (AFP) measurement, while surveillance is NOT recommended for non-cirrhotic MASH patients without severe fibrosis (F3). 1

Screening Algorithm Based on Fibrosis Stage

The 2024 EASL-EASD-EASO guidelines provide clear, fibrosis-stage-dependent recommendations:

Cirrhotic MASH (F4)

• Mandatory surveillance: Implement hepatocellular carcinoma monitoring programs 1
• Surveillance method: Semi-annual abdominal ultrasound PLUS AFP measurement 1
• Rationale: Ultrasound alone has low sensitivity for early HCC detection in MASLD patients with obesity; AFP combination improves detection 1

Severe Fibrosis (F3)

• Individualized approach: Surveillance may be considered based on individual risk assessment 1
• This is a weak recommendation reflecting emerging evidence that some F3 patients develop HCC
• Consider additional risk factors: type 2 diabetes, Hispanic ethnicity, PNPLA3 genetic variants 1

Non-Cirrhotic MASH Without Severe Fibrosis (<F3)

• No surveillance recommended 1
• Annual HCC incidence is too low to justify surveillance costs and harms
• Focus instead on preventing fibrosis progression

Critical Nuances for MASH Patients

Obesity complicates surveillance: Patients with MASLD and obesity have particularly poor ultrasound visualization, making AFP combination essential rather than optional 1. If ultrasound quality remains inadequate despite repeat attempts, cross-sectional MRI imaging should be undertaken 1.

Risk stratification matters: The guidelines acknowledge that certain high-risk features warrant closer monitoring even at F3 stage 1. Consider genetic risk profiling (PNPLA3 p.I148M variant) in specialized centers for personalizing surveillance intensity 1.

Common Pitfalls to Avoid

1. Don't screen non-cirrhotic MASH patients routinely: Despite MASH-HCC occurring in non-cirrhotic livers, population-level surveillance below F3 is not cost-effective given low absolute risk 1

2. Don't rely on ultrasound alone in obese patients: The combination of MASLD etiology and obesity creates a "perfect storm" for poor ultrasound sensitivity—always add AFP 1

3. Don't forget to assess fibrosis stage first: Surveillance decisions hinge entirely on accurate fibrosis staging using non-invasive tests (FIB-4, transient elastography) or biopsy 1

Surveillance Intervals and Methods

• Frequency: Every 6 months for cirrhotic patients 1
• Primary modality: Abdominal ultrasound + AFP (not ultrasound alone in MASLD) 1
• Alternative imaging: MRI for patients with persistent poor ultrasound visualization or dysplastic/regenerative nodules 1

The evidence strongly supports a binary approach: aggressive surveillance for cirrhosis, selective consideration for F3, and no routine surveillance for earlier stages, despite the reality that some MASH-HCC develops in non-cirrhotic livers 2, 3.